TITLE

Incretin drugs described as exciting new treatment option

PUB. DATE
November 2010
SOURCE
CMAJ: Canadian Medical Association Journal;Nov2010 CMA Conference Supplement, Vol. 182, p4
SOURCE TYPE
Academic Journal
DOC. TYPE
Proceeding
ABSTRACT
Information on several papers discussed during the symposium sponsored by Novo Nordisk A/S related to incretin therapies for diabetes is presented. Topics include the potentials of incretin therapies, the unmet medical needs of diabetics, and the cardiovascular effects of incretin. The meeting featured several experts on diabetes including doctor Bernard Zinman, doctor Alice Cheng, and doctor Mansoor Husain.
ACCESSION #
57483817

 

Related Articles

  • GLP-1 therapies fully integrating into diabetes practice.  // CMAJ: Canadian Medical Association Journal;11/20/2012 Conference Report Supplement, Vol. 184, p4 

    Information about a symposium held in 2012 sponsored by Novo Nordisk, on Glucagon-like peptide 1 (GLP-1) therapies for diabetes treatment is presented. Topics include the role of incretins, GLP-1 receptor agonists such as liraglutide and exenatide in reduced hypoglycemia and weight loss. The...

  • GLP-1s Center Stage at ADA, Marcadia/Lilly Deal. Morrison, Trista // BioWorld Today;6/29/2010, Vol. 21 Issue 124, p1 

    The article deals with the various glucagon-like peptide-1 (GLP-1) agonists featured at the 70th annual scientific sessions of the American Diabetes Association (ADA). A data presented by Novo Nordisk showed that its GLP-1 Victoza better reduced HbA1c, fasting plasma glucose and weight than...

  • Novo sets sights on obesity market with diabetes drug. Sheridan, Cormac // Nature Biotechnology;Nov2014, Vol. 32 Issue 11, p1071 

    The article focuses on pharmaceutical company Novo Nordisk's Saxenda (liraglutide) drug for obesity treatment, which has received approval to be marketed for type 2 diabetes by US Food and Drug Administration (FDA). Topics include details of Endocrinologic and Metabolic Drugs Advisory Committee...

  • Amylin and Novo Nordisk Battle For GLP-1 Market Dominance. Young, Donna // BioWorld Today;6/10/2008, Vol. 19 Issue 112, p3 

    This article focuses on the possible competition between Amylin Pharmaceuticals Inc. and Novo Nordisk AS in the glucagon-like peptide-1 (GLP-1) market. Byetta of Amylin Pharmaceuticals is the first and only U.S. Food and Drug Administration (FDA)-approved incretin mimetic for Type II diabetes...

  • Diabetes Drugmakers Shares Spiral on Split FDA Panel. Young, Donna // BioWorld Today;4/6/2009, Vol. 20 Issue 64, p1 

    The article reports on the result of voting by the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee on the safety of Novo Nordisk's diabetes drug liraglutide. Liraglutide is a once-daily human glucagon-like peptide-I analogue. According to the FDS,...

  • Oral GLP1 analogue rounds Phase II corner. Mullard, Asher // Nature Reviews Drug Discovery;Apr2015, Vol. 14 Issue 4, p227 

    The article discusses a Phase II trial of oral glucagon-like peptide 1 (GLP1) drug class conducted by Novo Nordisk A/S.

  • GLP-1.  // Diabetologia;Aug2000 Supplement 1, Vol. 43, pA30 

    The article presents abstracts of studies of glucagon-like peptide (GLP)-1, reported at the 36th annual meeting of the European Association for the Study of Diabetes in Jerusalem, from September 17 to 21, 2000. They include "Expression of the glucagon-like peptide-1 receptor and glucokinase in...

  • GLP-1 Analogues I.  // Diabetologia;Aug2000 Supplement 1, Vol. 43, pA144 

    The article presents abstracts of studies of glucagon-like peptide (GLP)-1 analogues, reported at the 36th annual meeting of the European Association for the Study of Diabetes in Jerusalem, from September 17 to 21, 2000. They include "Subcutaneous exendin-4 lowers both post-prandial and fasting...

  • GLP-1 Analogues II.  // Diabetologia;Aug2000 Supplement 1, Vol. 43, pA146 

    The article presents abstracts of studies of glucagon-like peptide (GLP)-1 analogues, reported at the 36th annual meeting of the European Association for the Study of Diabetes in Jerusalem, from September 17 to 21, 2000. They include "Decreased fasting GLP-1 levels in type-2 diabetes,"...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics